Apellis Pharmaceuticals (APLS) Short-Term Debt to Capital
Apellis Pharmaceuticals (APLS) is scaling the presence of its flagship retinal atrophy treatment across US and European markets. Its status as the exclusive developer in this field allows the company to implement premium pricing for the therapy. This price trend reflected below on GURU.Markets, where the indicator stands at 0.22, confirms the financial resilience of a business based on patients' lifelong need for treatment and patent protection that guarantees consistently high profits.
Metric breakdowns and analytics for apellis.com (APLS)
Conservative capital demands high financial stability; therefore, this indicator assesses the proportion of short-term liabilities relative to equity to determine liquidity risks. Low reliance on current loans, coupled with the monopoly position of Apellis Pharmaceuticals (APLS) with its drug Syfovre, minimizes the threat of share dilution, as confirmed by changes in the short-term debt-to-equity ratio.